Merck's blockbuster drug Keytruda and Eisai's cancer drug Lenvima, in combination with chemotherapy, failed to improve ...

The CEO of Germany's Merck KGaA said a recovery in sales growth at its existing business means it can take a cautious approach when it comes to buying other companies, which are expensively priced.